"rationale","description","label","instanceType","name","id","uuid:ID"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study","","StudyDesign","Study Design 1","StudyDesign_1","8c5915f2-8676-45aa-87a1-38eb0bb45043"
